
The policy is a drug-compounding framework, not a supplement pathway, but it changes the regulatory backdrop for peptide products, drug preclusion arguments, and gray-market competition.

Alicia Bigica is Vice President of Content at MJH Life Sciences.

The policy is a drug-compounding framework, not a supplement pathway, but it changes the regulatory backdrop for peptide products, drug preclusion arguments, and gray-market competition.

FDA's final NDI guidance sets identity and safety expectations. See what AHPA and CRN say remains unresolved and what it means for suppliers.